Events & Presentations

Presentation / Fact Sheet

Upcoming Events

Past Events

International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025)

September 12-15, 2025

Krakow, Poland

Presenter: Alexey V. Danilov, MD, PhD; Professor, Department of Hematology and Transplantation; City of Hope National Medical Center, Duarte, California

Topic: MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results from a Phase II randomized study.

6th ESCMID Conference on Vaccines: From Development to Real-World Clinical Practice and Global Health

September 10–13, 2025

Lisbon, Portugal

Presenter: Kelly T. McKee, Jr., MD, MPH; Chief Medical Officer, GeoVax Labs, Atlanta, Georgia
Topic: GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date.

H.C. Wainwright 27th Annual Global Investment Conference

September 8, 2025, 7:00 am ET

New York, NY

Webcast

Q2 2025 GeoVax Labs, Inc. Corporate Update

July 28, 2025 - 4:30 PM ET

Webcast

Emerging Growth Conference

July 16, 2025 - 1:10 PM ET

Webcast

BIO International Convention

June 16-19, 2025

Boston, MA

European Hematology Association (EHA) 2025 Hybrid Congress

June 12-15, 2025 - Milan, Italy and online

Poster Session 1 – Alexey V. Danilov, M.D., Ph.D., Associate Director of the Toni Stephenson Lymphoma Center and Professor in the Department of Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center in Duarte, California

Title: “MVA-Based GEO-CM04S1 Vaccine Results in Improved Cellular Immune Response in Patients with Chronic Lymphocytic Leukemia (CLL) Compared with mRNA-Based Vaccine: Initial Results of a Phase II Randomized Study”
When: June 14, 2025 - 18:30 - 18:30 CEST

Keystone Symposia on Vaccinology: Horizons Across Disease, Demography and Technology

June 4-7, 2025, Washington, DC

Poster Session 1 – Pratima Kumari, PhD, GeoVax Scientist

Poster Number: 1050
Title: “MVA‑vectored multi‑antigen COVID‑19 vaccines induce protective immunity against SARS‑CoV‑2 variants spanning Alpha to Omicron in preclinical animal models.”
When: June 5, 2025 at 12:00 p.m.

Poster Session 2 – Amany Elsharkawy, PhD, Georgia State University Scientist
Poster Number: 2047
Title: “GEO‑CM04S1 vaccine candidate maintains potent cross‑reactivity against original SARS‑CoV‑2 B.1 and Omicron subvariant XBB.1.5.”
When: June 6, 2025 at 7:30 p.m.

For more information on the Keystone Conference, please visit the Keystone Symposia website: https://www.keystonesymposia.org/conferences/conference-listing/meeting/onpage-program/g12025

Q1 2025 GeoVax Labs, Inc. Corporate Update

May 1, 2025 - 4:30 PM ET

Webcast

American Association of Cancer Research

April 25-30, 2025, Chicago, IL

Speaker:	J. Marc Pipas, MD, Executive Medical Director, Oncology
Session Title:	Viral-Vectored, Gene-Directed Prodrug Therapy (Gedeptin) in Needle-Accessible Solid Tumors

World Vaccine Congress Washington 2025

April 22-24, 2025

Speaker:

Don J. Diamond, PhD, Director, Division of Vaccine Research & Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center

Session Title:

Phase 2b Study Results That Evaluated and Compared GeoVax’s Multi-Antigen, Vaccine Candidate (GEO-CM04S1) to an Approved Vaccine Against COVID-19